Indaptus Therapeutics announces positive results from the second cohort of its Phase 1 INDP-D101 trial. Patients continue to exhibit a broad immune response similar to the first cohort. The preliminary results of this study were reviewed by the Company and an independent Safety Review Committee. Based on this review, it was recommended that the Company continue the trial and enroll patients for multiple doses of its lead therapeutic candidate, Decoy20. The company has immediately started screening potential patients. The primary goal of the next stage of the trial is to determine the safety of Decoy20 when administered multiple times to the same patient, and to begin to examine the efficacy across multiple types of cancer. In animal models, Decoy20 was shown to be safe in several multiple dosing schedules.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on INDP:
- Indaptus Therapeutics launches new social media initiative to provide education
- Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
- Indaptus Therapeutics to receive European patent for platform technology
- European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology
